Breaking News
Get 50% Off 0
Unlock Premium Data: Up to 50% Off InvestingPro CLAIM SALE
Close

AstraZeneca PLC ADR (AZNPy)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
73.000 0.000    0.00%
21/06 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 1
  • Bid/Ask: 73.500 / 75.000
  • Day's Range: 73.000 - 73.000
Type:  Equity
Market:  Germany
ISIN:  US0463531089 
S/N:  886715
AstraZeneca ADR 73.000 0.000 0.00%

AZNPy Financial Summary

 
A brief financial summary of AstraZeneca PLC ADR as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

AstraZeneca PLC reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 457 million compared to USD 286 million a year ago. Revenue was USD 12,679 million compared to USD 10,879 million a year ago. Net income was USD 2,179 million compared to USD 1,803 million a year ago. Basic earnings per share from continuing operations was USD 1.41 compared to USD 1.16 a year ago. Diluted earnings per share from continuing operations was USD 1.4 compared to USD 1.16 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

AZNPy Income Statement

Gross margin TTM 82.5%
Operating margin TTM 23.53%
Net Profit margin TTM 13.3%
Return on Investment TTM 13.08%
 Total Revenue  Net Income
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Revenue 12679 12024 11492 11416
Gross Profit 10481 9729 9437 9499
Operating Income 3310 2034 2533 2602
Net Income 2179 960 1374 1818

AZNPy Balance Sheet

Quick Ratio MRQ 0.66
Current Ratio MRQ 0.89
LT Debt to Equity MRQ 72.93%
Total Debt to Equity MRQ 92.65%
 Total Assets  Total Liabilities
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Total Assets 102293 101119 96086 96543
Total Liabilities 64792 61953 58865 59127
Total Equity 37501 39166 37221 37416

AZNPy Cash Flow Statement

Cash Flow/Share TTM 6.26
Revenue/Share TTM 30.71
Operating Cash Flow  8.60%
 Cash  Net Change in Cash
Period Ending: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 2486 2380 3114 1718
Cash From Investing Activities -2413 -1077 -1221 -520
Cash From Financing Activities 2028 -291 -2726 -1519
Net Change in Cash 2055 1018 -852 -357
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AZN Comments

Write your thoughts about AstraZeneca PLC DRC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email